This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


peer-reviewed publication

trusted source


Specific gene expression in B-cell subset found to inhibit anti-tumor T-cell activation

Specific gene expression in B-cell subset found to inhibit anti-tumor T-cell activation
Characterization of B cells expressing TIM-1 and several checkpoint molecules in mouse melanoma and human tumors. Credit: Nature (2023). DOI: 10.1038/s41586-023-06231-0

Immunology research led by Harvard Medical School has taken a closer look at the role of B-cells in fighting cancer. In a paper, "B-cell-specific checkpoint molecules that regulate anti-tumor immunity," published in Nature, the team identifies a critical checkpoint of B-cell activation and how bypassing the checkpoint could unlock T-cell potential.

Researchers used high-throughput flow cytometry, bulk and single-cell RNA-sequencing to study various B-cell types during melanoma growth and monitored gene expression levels.

They found that the depletion of B-cells globally significantly enhanced melanoma tumor growth.

A subset of B-cells that specifically expands in the draining lymph node in tumor-bearing mice was identified. This expanding B-cell subset expresses the cell surface molecule TIM-1, encoded by the gene Havcr1. The subset also expresses co-inhibitory molecules such as PD-1, TIM-3, TIGIT, and LAG-3.

Conditional deletion of the co-inhibitory molecules on B-cells had little or no effect on tumor burden. However, selective deletion of Havcr1 in B-cells significantly inhibited tumor growth.

With the loss of Havcr1 in knock-out mice, the accompanying absence of TIM-1 led to increased B-cell activation and antigen presentation resulting in the expansion of tumor-specific T-cell activity.

Administration of a commercially available high-affinity anti-TIM-1 antibody also inhibited tumor growth. Removal of the Havcr1 gene from T-cells had no effect, isolating the effect as B-cell dependent.

Specific B-cell tumor-related mechanisms are poorly understood in comparison to T-cells. More generally, it is a through a cascade of intracellular signaling to mount an effective immune response against pathogens. Within this system, there are signals that both initiate and regulate immune response activities.

This specific B-cell subset expression of TIM-1 may function as a healthy regulatory check on T-cell activation, suppressing excessive response. That healthy function could be unconnected to tumor growth, putting it at odds with the ability of the immune system to mount a more active attack on tumor cells.

B-cell responses have previously been associated with in multiple cancers by fostering intratumoral B-cell and T-cell cooperation. The data in this study suggest that TIM-1 can causally limit B-cell activation, antigen presentation and T-cell activation.

Manipulation or suppression of TIM-1-expressing B-cells could have a therapeutic advantage in allowing the immune system to mobilize anti-tumor immunity and inhibit .

More information: Lloyd Bod et al, B-cell-specific checkpoint molecules that regulate anti-tumour immunity, Nature (2023). DOI: 10.1038/s41586-023-06231-0

Uncovering a role for B cells in antitumour immunity, Nature (2023). DOI: 10.1038/d41586-023-01678-7

Journal information: Nature

© 2023 Science X Network

Citation: Specific gene expression in B-cell subset found to inhibit anti-tumor T-cell activation (2023, June 23) retrieved 25 February 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

The benefits of anti-CD69 antibodies for future cancer therapies


Feedback to editors